New Zealand markets open in 6 hours 15 minutes
  • NZX 50

    12,718.91
    +187.25 (+1.49%)
     
  • NZD/USD

    0.6836
    +0.0010 (+0.15%)
     
  • ALL ORDS

    7,587.40
    +24.90 (+0.33%)
     
  • OIL

    67.62
    -2.33 (-3.33%)
     
  • GOLD

    1,797.00
    +11.80 (+0.66%)
     

Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?

·4-min read
Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?

Earlier this month, Merck (NYSE: MRK) announced it was ending clinical trials of its antiviral pill candidate for treating COVID-19, molnupiravir, on account of the potential therapy's high level of effectiveness. Take Gilead Sciences' (NASDAQ: GILD) antiviral drug, remdesivir. Will Merck's drug follow a similar or better path?

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting